Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine

Roberto A. Dominguez, Adarsh Kumar, William Cua

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pharmacokinetic interactions are possible with the prescription of two or more psychotropics. This caution could also apply to the proximal use of selective serotonin (5-hydroxytryptamine) reuptake inhibitors (SSRIs), especially those that may be potent inhibitors of specific hepatic metabolizing enzyme systems. Both fluoxetine (FLX) and paroxetine (PAR) are inhibitors of the cytochrome P4502D6 enzyme system. In order to assess the potential pharmacokinetic interactions between these two SSRIs, nine patients were first treated with fixed therapeutic doses of FLX for a minimum of 6 weeks. Subsequently, in a double-blind design, some of these patients were abruptly switched to PAR, 20 mg/day, and others were switched to placebo. Serum levels of FLX, norfluoxetine (NFLX), and PAR were collected before and at specific points after the switch. The results suggest that the clearance kinetics of FLX and NFLX are not affected by the abrupt switch to PAR. it was not possible to determine whether the kinetics of PAR were influenced by the residual FLX and NFLX concentrations.

Original languageEnglish
Pages (from-to)320-323
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume16
Issue number4
DOIs
StatePublished - Aug 1 1996

Fingerprint

Paroxetine
Fluoxetine
Serotonin
Pharmacokinetics
Enzymes
Cytochromes
Prescriptions
Placebos
norfluoxetine
Liver
Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine. / Dominguez, Roberto A.; Kumar, Adarsh; Cua, William.

In: Journal of Clinical Psychopharmacology, Vol. 16, No. 4, 01.08.1996, p. 320-323.

Research output: Contribution to journalArticle

Dominguez, Roberto A. ; Kumar, Adarsh ; Cua, William. / Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine. In: Journal of Clinical Psychopharmacology. 1996 ; Vol. 16, No. 4. pp. 320-323.
@article{d9e9a6a03f384b068cebe93abbf61c7a,
title = "Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine",
abstract = "Pharmacokinetic interactions are possible with the prescription of two or more psychotropics. This caution could also apply to the proximal use of selective serotonin (5-hydroxytryptamine) reuptake inhibitors (SSRIs), especially those that may be potent inhibitors of specific hepatic metabolizing enzyme systems. Both fluoxetine (FLX) and paroxetine (PAR) are inhibitors of the cytochrome P4502D6 enzyme system. In order to assess the potential pharmacokinetic interactions between these two SSRIs, nine patients were first treated with fixed therapeutic doses of FLX for a minimum of 6 weeks. Subsequently, in a double-blind design, some of these patients were abruptly switched to PAR, 20 mg/day, and others were switched to placebo. Serum levels of FLX, norfluoxetine (NFLX), and PAR were collected before and at specific points after the switch. The results suggest that the clearance kinetics of FLX and NFLX are not affected by the abrupt switch to PAR. it was not possible to determine whether the kinetics of PAR were influenced by the residual FLX and NFLX concentrations.",
author = "Dominguez, {Roberto A.} and Adarsh Kumar and William Cua",
year = "1996",
month = "8",
day = "1",
doi = "10.1097/00004714-199608000-00008",
language = "English",
volume = "16",
pages = "320--323",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine

AU - Dominguez, Roberto A.

AU - Kumar, Adarsh

AU - Cua, William

PY - 1996/8/1

Y1 - 1996/8/1

N2 - Pharmacokinetic interactions are possible with the prescription of two or more psychotropics. This caution could also apply to the proximal use of selective serotonin (5-hydroxytryptamine) reuptake inhibitors (SSRIs), especially those that may be potent inhibitors of specific hepatic metabolizing enzyme systems. Both fluoxetine (FLX) and paroxetine (PAR) are inhibitors of the cytochrome P4502D6 enzyme system. In order to assess the potential pharmacokinetic interactions between these two SSRIs, nine patients were first treated with fixed therapeutic doses of FLX for a minimum of 6 weeks. Subsequently, in a double-blind design, some of these patients were abruptly switched to PAR, 20 mg/day, and others were switched to placebo. Serum levels of FLX, norfluoxetine (NFLX), and PAR were collected before and at specific points after the switch. The results suggest that the clearance kinetics of FLX and NFLX are not affected by the abrupt switch to PAR. it was not possible to determine whether the kinetics of PAR were influenced by the residual FLX and NFLX concentrations.

AB - Pharmacokinetic interactions are possible with the prescription of two or more psychotropics. This caution could also apply to the proximal use of selective serotonin (5-hydroxytryptamine) reuptake inhibitors (SSRIs), especially those that may be potent inhibitors of specific hepatic metabolizing enzyme systems. Both fluoxetine (FLX) and paroxetine (PAR) are inhibitors of the cytochrome P4502D6 enzyme system. In order to assess the potential pharmacokinetic interactions between these two SSRIs, nine patients were first treated with fixed therapeutic doses of FLX for a minimum of 6 weeks. Subsequently, in a double-blind design, some of these patients were abruptly switched to PAR, 20 mg/day, and others were switched to placebo. Serum levels of FLX, norfluoxetine (NFLX), and PAR were collected before and at specific points after the switch. The results suggest that the clearance kinetics of FLX and NFLX are not affected by the abrupt switch to PAR. it was not possible to determine whether the kinetics of PAR were influenced by the residual FLX and NFLX concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0030036427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030036427&partnerID=8YFLogxK

U2 - 10.1097/00004714-199608000-00008

DO - 10.1097/00004714-199608000-00008

M3 - Article

C2 - 8835708

AN - SCOPUS:0030036427

VL - 16

SP - 320

EP - 323

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -